Hemoglobinopathies Market Insights, Review and Outlook to 2022: Hexa Reports

Submitted by: Submitted by

Views: 10

Words: 1044

Pages: 5

Category: Business and Industry

Date Submitted: 06/07/2016 01:59 AM

Report This Essay

Hexa Reports

Market Research Reports and Insightful Company Profiles

Hemoglobinopathies Market Share, Size, Market Insights,

Trends, Market Review and Outlook, Overview And

Segment Forecasts To 2022

Global hemoglobinopathies market is expected to reach over USD 8.82 billion by 2022 according to a

new report by Grand View Research Inc. Rising prevalence of hemoglobin disorders such as sickle cell

anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering drivers of the market.

According to the WHO, hemoglobin disorders are endemic in over 60% of 229 countries affecting over

70% of births. It is also reported that minimum 5% of the world population are carriers of significant

variation.

Prevalence of hemoglobinopathies is high in low-income countries such as Sub Saharan region and

South East Asia. 85% of the affected population in the U.S. and Europe has ancestral base in these

regions.

Browse Detail Report With TOC @

http://www.hexareports.com/report/hemoglobinopathies-market/details

Governments are collaborating with local institutes to undertake awareness programs for curbing the

effect of hemoglobinopathies-related mortality rate. For instance, Thalassemia Data Collection Project

and Registry and Surveillance System for Hemoglobinopathies (RuSH) projects were started in 2010 by

the Centers for Disease Control and Prevention (CDC).

Hexa Reports

Market Research Reports and Insightful Company Profiles

Low level of hygiene, insufficient healthcare infrastructure, and lesser awareness levels are some key

factors attributing to increase in base of target population in low-income regions such as South East

Asia, Mediterranean basin, and Africa.

Further key findings from the study suggest:

The market for Sickle Cell Disease (SCD) was the largest with revenue valued at over USD 2,290.0 million

in 2014. Rising prevalence of hemoglobinopathies and presence of strong product pipeline for sickle cell

anemia such as HQK-1001 and Luspatercept are...